Literature DB >> 8529134

Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.

S Salvadori1, M Attila, G Balboni, C Bianchi, S D Bryant, O Crescenzi, R Guerrini, D Picone, T Tancredi, P A Temussi.   

Abstract

BACKGROUND: Tyr-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) and Tyr-Tic-Ala were the first peptides with delta opioid antagonist activity lacking Phe, considered essential for opioid activity based on the N-terminal tripeptide sequence (Tyr-D-Xaa-Phe) of amphibian skin opioids. Analogs were then designed to restrain the rotational flexibility of Tyr by the substitution of 2,6-dimethyl-L-tyrosine (Dmt).
MATERIALS AND METHODS: Tyr and Dmt peptides were synthesized by solid phase and solution methods using Fmoc technology or condensing Boc-Dmt-OH or Boc-Tyr(But)-OH with H-L-Tic-OBut or H-D-Tic-OBut, respectively. Peptides were purified (> 99%) by HPLC and characteristics determined by 1H-NMR, FAB-MS, melting point, TLC, and amino acid analyses.
RESULTS: H-Dmt-Tic-OH had high affinity (Ki delta = 0.022 nM) and extraordinary selectivity (Ki mu/Ki delta = 150,000); H-Dmt-Tic-Ala-OH had a Ki delta = 0.29 nM and delta selectivity = 20,000. Affinity and selectivity increased 8700- and 1000-fold relative to H-Tyr-Tic-OH, respectively. H-Dmt-Tic-OH and H-Dmt-Tic-NH2 fitted one-site receptor binding models (eta = 0.939-0.987), while H-Dmt-Tic-ol, H-Dmt-Tic-Ala-OH and H-Dmt-Tic-Ala-NH2 best fitted two-site models (eta = 0.708-0.801, F 18.9-26.0, p < 0.0001). Amidation increased mu affinity by 10- to 100-fold and acted synergistically with D-Tic2 to reverse selectivity (delta-->mu). Dmt-Tic di- and tripeptides exhibited delta antagonist bioactivity (Ke = 4-66 nM) with mouse vas deferens and lacked agonist mu activity (> 10 microM) in guinea-pig ileum preparations. Dmt-Tic analogs weakly interacted with kappa receptors in the 1 to > 20 microM range.
CONCLUSIONS: Dmt-Tic opioidmimetic peptides represent a highly potent class of opioid peptide antagonists with greater potency than the nonopioid delta antagonist naltrindole and have potential application as clinical and therapeutic compounds.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529134      PMCID: PMC2229973     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  53 in total

1.  Opioid receptor selectivity reversal in deltorphin tetrapeptide analogues.

Authors:  L H Lazarus; S Salvadori; R Tomatis; W E Wilson
Journal:  Biochem Biophys Res Commun       Date:  1991-07-15       Impact factor: 3.575

Review 2.  Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists.

Authors:  P S Portoghese
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

3.  Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high mu opioid receptor selectivity.

Authors:  P W Schiller; T M Nguyen; N N Chung; C Lemieux
Journal:  J Med Chem       Date:  1989-03       Impact factor: 7.446

4.  New features of the delta opioid receptor: conformational properties of deltorphin I analogues.

Authors:  G Balboni; M Marastoni; D Picone; S Salvadori; T Tancredi; P A Temussi; R Tomatis
Journal:  Biochem Biophys Res Commun       Date:  1990-06-15       Impact factor: 3.575

5.  Differential contribution of C-terminal regions of dermorphin and dermenkephalin to opioid-sites selection and binding potency.

Authors:  S Sagan; M Amiche; A Delfour; A Camus; A Mor; P Nicolas
Journal:  Biochem Biophys Res Commun       Date:  1989-09-15       Impact factor: 3.575

6.  Molecular determinants of receptor affinity and selectivity of the natural delta-opioid agonist, dermenkephalin.

Authors:  S Sagan; M Amiche; A Delfour; A Mor; A Camus; P Nicolas
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

7.  Function of negative charge in the "address domain" of deltorphins.

Authors:  L H Lazarus; S Salvadori; V Santagada; R Tomatis; W E Wilson
Journal:  J Med Chem       Date:  1991-04       Impact factor: 7.446

8.  Structure-activity relationships of the delta-opioid-selective agonists, deltorphins.

Authors:  P Melchiorri; L Negri; G Falconieri-Erspamer; C Severini; R Corsi; M Soaje; V Erspamer; D Barra
Journal:  Eur J Pharmacol       Date:  1991-03-26       Impact factor: 4.432

9.  Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.

Authors:  P W Schiller; G Weltrowska; T M Nguyen; C Lemieux; N N Chung; B J Marsden; B C Wilkes
Journal:  J Med Chem       Date:  1991-10       Impact factor: 7.446

10.  Conversion of enkephalin and dermorphin into delta-selective opioid antagonists by single-residue substitution.

Authors:  T Tancredi; S Salvadori; P Amodeo; D Picone; L H Lazarus; S D Bryant; R Guerrini; G Marzola; P A Temussi
Journal:  Eur J Biochem       Date:  1994-08-15
View more
  28 in total

1.  Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.

Authors:  Allison S Cohen; Renata Patek; Steven A Enkemann; Joseph O Johnson; Tingan Chen; Eric Toloza; Josef Vagner; David L Morse
Journal:  Bioconjug Chem       Date:  2015-10-30       Impact factor: 4.774

2.  Synthesis of 3,6-bis[H-Tyr/H-Dmt-NH(CH2)m,n]-2(1H)pyrazinone derivatives: function of alkyl chain length on opioid activity.

Authors:  Kimitaka Shiotani; Tingyou Li; Anna Miyazaki; Yuko Tsuda; Sharon D Bryant; Akihiro Ambo; Yusuke Sasaki; Lawrence H Lazarus; Yoshio Okada
Journal:  Bioorg Med Chem Lett       Date:  2006-09-01       Impact factor: 2.823

3.  Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.

Authors:  Gianfranco Balboni; Valentina Onnis; Cenzo Congiu; Margherita Zotti; Yusuke Sasaki; Akihiro Ambo; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Claudio Trapella; Severo Salvadori
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

4.  New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.

Authors:  John L Neumeyer; Xuemei Peng; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Severo Salvadori; Claudio Trapella; Gianfranco Balboni
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

5.  Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors.

Authors:  Yeon Sun Lee; Joel Nyberg; Sharif Moye; Richard S Agnes; Peg Davis; Shou-wu Ma; Josephine Lai; Frank Porreca; Ruben Vardanyan; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2007-02-08       Impact factor: 2.823

6.  Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.

Authors:  Tingyou Li; Kimitaka Shiotani; Anna Miyazaki; Yuko Tsuda; Akihiro Ambo; Yusuke Sasaki; Yunden Jinsmaa; Ewa Marczak; Sharon D Bryant; Lawrence H Lazarus; Yoshio Okada
Journal:  J Med Chem       Date:  2007-05-12       Impact factor: 7.446

7.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

8.  Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Claudio Trapella; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Xuemei Peng; John L Neumeyer
Journal:  ACS Chem Neurosci       Date:  2010-02-17       Impact factor: 4.418

9.  Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).

Authors:  Gianfranco Balboni; Remo Guerrini; Severo Salvadori; Lucia Negri; Elisa Giannini; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

10.  Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging.

Authors:  Jatinder S Josan; David L Morse; Liping Xu; Maria Trissal; Brenda Baggett; Peg Davis; Josef Vagner; Robert J Gillies; Victor J Hruby
Journal:  Org Lett       Date:  2009-06-18       Impact factor: 6.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.